Precision Epigenomics wins AZBio Fast Lane honor

Precision Epigenomics was named a 2026 AZBio Fast Lane Award honoree for progress in commercializing its EPISEEK multi-cancer early detection blood test. The recognition spotlights the Tucson company’s clinical, laboratory and partnership milestones as it expands access to earlier cancer screening, including for firefighters and other high-risk groups.

Why it matters: - Precision Epigenomics is being recognized for moving an early cancer detection platform from development into clinical use and commercialization. - The award highlights Arizona’s bioscience sector and the push to make multi-cancer screening more accessible for high-risk patients. - The company’s work is aimed at identifying cancer earlier, when treatment options are often broader.

What happened: - Precision Epigenomics Inc. was named a 2026 AZBio Fast Lane Award honoree by the Arizona Bioindustry Association. - The Tucson-based company will be formally honored Oct. 7, 2026, at the 23rd Annual AZBio Awards at the Phoenix Convention Center. - The recognition covers milestones achieved over the past 18 months. - The award comes as Precision Epigenomics advances EPISEEK, its multi-cancer early detection blood test.

The details: - EPISEEK is a blood-based test that looks for cancer-associated epigenetic changes in cell-free DNA. - The platform analyzes methylation patterns associated with multiple cancer types from a single blood sample. - Precision Epigenomics says EPISEEK can identify signals tied to more than 70 cancer types. - The company says EPISEEK is the only MCED test on the market that detects brain cancer. - Precision Epigenomics operates a CLIA-certified, CAP-accredited molecular pathology laboratory in Tucson. - The laboratory supports clinical testing and further development of the company’s liquid biopsy platform. - The company is also developing additional molecular diagnostic applications targeting cancers. - Precision Epigenomics was founded as a University of Arizona spinout focused on cancer epigenetics research. - The company has expanded its provider network, strategic commercial partnerships, clinical studies, laboratory infrastructure, and work on regulatory and reimbursement pathways. - Precision Epigenomics is developing next-generation versions of EPISEEK to improve diagnostic performance and broaden clinical uses.

Between the lines: - The award suggests the company has reached a credibility milestone with investors, partners and potential clinical users. - Firefighters and other first responders are a focus because of elevated occupational cancer risk. - Precision Epigenomics has positioned first responders as an early entry point for occupational cancer screening programs. - The company’s push into occupational health signals a broader strategy to reach populations that may benefit from routine surveillance before symptoms appear.

What’s next: - Precision Epigenomics plans to keep expanding clinical validation and market access for EPISEEK. - The company is continuing to build partnerships that can bring the test into occupational health programs. - Precision Epigenomics is pursuing regulatory and reimbursement pathways that could support broader adoption. - The company also expects to advance next-generation versions of its platform. - For more information, contact Jannalee Johnson at jjohnson@Precision-Epigenomics.com.

The bottom line: - Precision Epigenomics is using the AZBio honor to showcase momentum as it tries to turn epigenetic cancer detection into a routine clinical tool.